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The t(1;19) translocation that characterizes 25% of pediatric pre-B cell acute lymphoblastic leukemias (pre-B 
ALL} produces a chimeric gene, joining 5' sequences that encode a transcriptional ctivator domain of E2A 
with 3' sequences that, in part, encode a homeo box domain of a new gene called pbxl. Two E2A-pbxl 
transcripts have been cloned. They encode the putative fusion proteins, p85 E2A-pbxl and p77 E2A-pbxl, which 
differ in Pbxl sequences alone, containing unique carboxyl termini whose sequences diverge after the Pbxl 
homeo box. In this study, an antiserum to Pbxl was used to investigate the identity and abundance of 
E2A-Pbxl fusion proteins in both the pre-B ALL cell line, 697, and in cryopreserved leukemic bone marrow 
cells, obtained from six children with t(1;19)-positive pre-B ALL. Five species of E2A-Pbxl proteins were 
identified in all cells containing t(l;19), two of which were indistinguishable from in vitro-translated 
p85 E2A-pbxl and p77 E2A-pbxl. To assess the biological properties of p85 E2A-pbxl and p77 F2A-pbxl in fibroblasts, 
the cDNAs encoding these proteins were cloned into retroviral vectors, and each was introduced into 
NIH-3T3 cells. Both p85 E2A-vbxl and p77 E2A-pbxl are localized in the nucleus, and expression of either resulted 
in malignant conversion of NIH-3T3 cells as assayed by tumor formation in nude mice. When scored by focus 
formation, density-independent growth, and growth in agar assays, p77 E2A-pbxt was a much more potent 
transforming protein than was p85 E2A-rbX~. Because subtle mutations in p85 E2A-pbxl converted its 
transforming activity into that of p77 E2A-pbxt, we suggest hat a sequence within the unique carboxyl 
terminus of p85 E2A-pbxl serves to negatively regulate its biochemical activity. 
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The binding of potential transcription factors to specific 
DNA sequences in the immunoglobulin heavy- and 
light-chain enhancers was first observed by footprinting 
studies both in vitro and in vivo {Church et al. 1985; 
Ephrussi et al. 19851. The KE2 DNA sequence motif, con- 
tained in the immunoglobulin K light-chain enhancer, 
was subsequently shown to be important in the tran- 
scriptional activation of this gene, because mutation of 
this sequence diminishes the strength of the K enhancer 
[Sen and Baltimore 1986; Lenardo et al. 1987}. Both the 
E2A and ITF-2 genes encode proteins that bind the KE2 
motif, each behaves as a transcriptional ctivator (Murre 
1989a; Henthom et al. 1990), and together they share 
considerable amino acid identity. Two domains in the 
E2A protein have been characterized--an mino-termi- 
nal domain that activates transcription and a carboxy- 
terminal domain involved in sequence-specific DNA- 
binding and imer formation with other cellular tran- 
scription factors {Murre 1989a, b; Davis et al. 1990; 
Henthom et al. 1990; Voronova and Baltimore 1990}. In 
contrast to the normal role of E2A in transcriptional reg- 
ulation, the occurrence of a mutant form of E2A in hu- 
man pre-B ALL {Kamps et al. 1990} suggests that it may 
also be involved in aberrant transcription and leukemic 
tumorigenesis. 
The breakpoint of the t( 1; 19)( q23;p 13.3) translocation, 
which is evident cytogenetically in 25% of pediatric pre- 
B ALL (Carroll et al. 1984; Williams et al. 1984} and is 
associated with a poor prognosis iCrist et al. 1990; Rai- 
mondi et al. 1990}, has been mapped within the E2A 
gene, which resides at 19p13.3 (Mellentin et al. 1989). 
Using an E2A cDNA probe, chimeric cDNAs containing 
sequences from both E2A and a second uncharacterized 
gene, previously designated prl, but now renamed pbxl, 
were isolated from the t{1;19}-positive pre-B ALL cell 
lines, 697 {Kamps et al. 19901 and SUP-B27 (Nourse et al. 
1990). prl was renamed pbxl to avoid confusion with the 
prolactin locus, which is also designated PRL. The fusion 
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proteins predicted by E2A-pbxl transcripts contain the 
amino-terminal trans-activation domain of E2A but 
have the carboxy-terminal DNA-binding and dimeriza- 
tion domain of E2A replaced with a homeo box encoded 
by pbxl. The sequence of the Pbxl borneo box is not 
identical to that of any other but does contain a remark- 
able 19 of 27 amino acid identity in its carboxy-terminal 
half to that of the yeast MATal protein, a transcription 
factor that, together with the MATcxl protein, represses 
haploid-specific gene expression and allows sporulation 
to occur (Miller et al. 1985; Nasmyth and Shore 1987). 
The reciprocal translation product, composed of the 5' 
portion of pbxl and the 3' portion of E2A, is not involved 
in the development of t(1;19)-containing pre-B ALL be- 
cause it is contained on the der (1) chromosome, which is 
lost from the leukemic cells in >80% of cases examined 
(Mellentin et al. 1989) and because transcriptional regu- 
lation of this locus, when it remains intact, is mediated 
by the pbxl promoter, which is silent in pre-B and ma- 
ture B cells (Kamps et al. 1990; Nourse et al. 1990). The 
domain structure of E2A-Pbxl proteins suggests that 
their potential contribution to the development of pre-B 
ALL is the activation of Pbxl-responsive genes by the 
E2A trans-activation domain in either pre-B cells or their 
progenitors. 
Two E2A-pbxl transcripts, likely the result of alter- 
native splicing, have been cloned and sequenced (Kamps 
et al. 1990; Nourse et al. 1990). They are designated type 
I and type II and encode the putative fusion polypeptides, 
p85 ExA-Pbxl and p77 E2A-Pbxl, which differ at their car- 
boxy-terminal ends. The goals of this study were to iden- 
tify the forms of E2A-Pbx 1 proteins contained in leuke- 
mic cells having the t(1;19) translocation and investigate 
the transforming potential of these fusion proteins in 
NIH-3T3 fibroblasts. We find that a family of E2A-Pbxl 
proteins, including p85 E2A-vbxl and p77 E2A-Pbxl, arise as 
a consequence of the t(1;19) translocation, and that E2A- 
Pbxl proteins are oncoproteins whose specific activities 
appear dependent on their unique carboxyl termini. 
Resu l ts  
Antibodies to Pbxl bind five species of E2A-Pbxl 
fusion proteins 
Previously (Kamps et al. 1990}, we reported that 697 
cells, which contain the t(1; 19) translocation, contain a 
new, 90-kD, E2A-related polypeptide, in addition to nor- 
mal E2A proteins. This novel protein was predicted tobe 
the translocation product of the cloned type I E2A-pbxl 
fusion transcript. At this time, the putative 77-kD prod- 
uct of the type II E2A-pbxl transcript was not identified 
in immunoprecipitates from 697 cells using antibodies 
reactive with E2A. To separate E2A-Pbxl fusion pro- 
teins from normal E2A proteins in 697 cells and then 
compare their primary structures to that of in vitro- 
translated p85 E2A-vbxl and p77 E2A-pbxl, a rabbit antise- 
rum was raised against Pbxl {see Materials and methods) 
and used to isolate Pbxl-containing polypeptides from 
697 cells by immunoprecipitation. Five proteins were 
E2A-Pbxl chimeric homeo box gene and leukemia 
immunoprecipitated by the anti-Pbxl serum (Fig. 1, lane 
6), two of which comigrated with in vitro-translated 
p77 E2^-Pbxl and p85 E2A-pbxl (lanes 7 and 8). None of the 
five proteins was immunoprecipitated from Nalm-6 
cells, a human pre-B cell line that lacks the t( 1; 19) trans- 
location (lane 3) or by a nonspecific antiserum to the 
retinoblastoma protein, p110 Rb {lanes 1 and 4). Although 
the two proteins that comigrated with in vitro-translated 
p85 E2A-pbxl and p77 E2A-pbxl are detectable in immuno- 
precipitates from 697 cells using an antiserum to E2A, 
the remaining three were obscured by polypeptides reac- 
tive with antibodies to E2A (lane 5} and, therefore, were 
not observed earlier. These results demonstrate that a 
family of at least five proteins, expressed specifically in 
697 cells, are immunoprecipitated by anti-Pbxl serum 
because they either contain Pbxl, are associated with a 
Pbxl-containing protein, or cross-react with anti-Pbxl 
antibodies. 
To distinguish among these possibilities, apartial pro- 
teolysis assay using Staphylococcus aureus V8 protease 
was developed {Cleveland et al. 1977). A distinctive pat- 
tern of peptides resulted from partial proteolysis of 
p85 E2A-Pbxl and p77 E2A-Pbxl with 5, 15, or 50 ng of S. 
aureus V8 protease, followed by resolution by poly- 
acrylamide gel electrophoresis {PAGE}. The pattern ob- 
tained by digestion with 50 ng of protease was used to 
typify E2A-Pbxl proteins and to discriminate between 
Nalm-6 697 
E2A E2A 
Rb PbxRb Pbx 
Rb- . :  
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Figure 1. Immunoprecipitation with antibodies to E2A and 
Pbxl. Nalm-6 cells, a human pre-B cell line that does not con- 
tain the t( 1; 191 translocation, and 697 cells, which contain the 
translocation, were labeled biosynthetically with [aSS]methio- 
nine and subjected to immunoprecipitation with a control an- 
tiserum against he retinoblastoma protein {designated Rbl, an 
antiserum against E2A [designed E2AI, and an antiserum to 
Pbxl (designated Pbxl). p77 E2A-Pbxl and p8S E2A-Pbxl markers 
were translated from RNA, transcribed in vitro from the type H 
and type I E2A-pbxl cDNAs, and analyzed in the last two lanes. 
The mobility of p110 ga, p85 E2A-pbxl, and p77 E2A-pbxt are indi- 
cated (le[t and right). The location of the five bands immuno- 
precipitated with the anti-Pbxl serum are indicated by dashes in 
lane 6. The major polypeptide that is immunoprecipitated by 
anti-E2A serum from 697 cells is indicated by the arrow. 
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p85 E2A-Pbxl and p77 E2A-vbxl (Fig. 2B). In vitro-translated 
p85 E2a-vbxl and p77 E2A-vb'l each contained major pro- 
teolytic fragments of 46, 33, and 20 kD (peptides A, B, 
and D, respectively); however, only p85 E~a-vbxl con- 
tained a major polypeptide of -24 kD (peptide C). This 
fragment is most likely derived from the carboxyl termi- 
nus of p85 E2A-vbxl, which contains an additional three 
methionines not present in p77 E2A-vbxl (Fig. 2A}. Pro- 
teins precipitated from 697 cells with antibodies to 
Pbxl were given numerical assignments indicated in Fig- 
ure 2C. The partial proteolytic pattern produced by 
p85 E2A-vbxl translated in vitro was identical to the major 
protein precipitated from 697 cells by antibodies to Pbxl 
(Fig. 2D, lanes 1 and 2), as well as to that of the new 
antigen precipitated from 697 cells by antibodies to E2A 
{data not shown). This demonstrated that translation of 
the type I E2A-pbxl transcript we cloned from 697 cells 
produces the major novel antigen detected both by anti- 
bodies to E2A and Pbxl. Partial proteolysis of band 4 {Fig. 
2D, lane 4) produced a pattern of polypeptides identical 
to that of in vitro-translated p77 EzA-vbx~ (Fig. 2B, lane 77, 
under the 50 ng heading), each lacking peptide C. Con- 
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F igure  2. Proteolytic analysis of polypeptides immunopreclp- 
itated by antibodies to Pbxl. (A) Comparative structures pre- 
dicted for the proteins p85 E2 -^pbx~ and p77 E2^-vb']. The stippled 
region is E2A, and the remainder ofthe polypeptide is Pbx 1. The 
horizontal stripes at the end of p77 r'2^-vbxl indicate its unique 
carboxyl terminus, and the black rectangle denotes the location 
of the homeo box in Pbxl. The solid circles represent the posi- 
tions of methionine r sidues in each protein. {B} Peptide pat- 
terns of p85 E2A-vbxl and p77 E2A-vbxl after digestion with the 
indicated amounts of S. aureus V8 protease and resolution by 
SDS-PAGE. (85) p85E2A-Vbxl; {77) p77 E2A-vbxl. Relative molecu- 
lar masses are indicated at left; peptide assignments are shown 
at right. (C) Pattern of E2A-Pbxl proteins obtained from an 
anti-Pbxl immunoprecipitation of 697 cells that results from 
twice the normal time of electrophoresis in SDS-PAGE and no 
enhancement of the autoradiographic signal. The band assign- 
ments used in the text are indicated to the side of the proteins 
they represent. (D) Comparison of peptides generated by diges- 
tion with 50 ng of S. aureus V8 protease of in vitro-translated 
p85 E2A-Pbxl and of bands 1 and 5 (shown in C, designed 1-5 at 
top of lane). Peptides A-D are designated atleft. 
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Figure 3. Identification of E2A-Pbxl proteins in lymphoblasts 
from t{1;19)-positive pre-B ALL patients. {A) Immunoprecipita- 
tions, using an antiserum to either Rb (first of each of two lanes) 
or Pbxl (second of each of two lanes), from six samples of bone 
marrow lymphoblasts, labeled biosynthetically with [aSS]methi- 
onine. Sets of immunoprecipitations are designated by the first 
two letters of the patient's last name. The migration of Rb is 
indicated at left, and that of in vitro-translated p85 E2A-vbxl and 
p77 E2A-Pbxl, at right. The migrations of E2A-Pbxl proteins 1-5 
are indicated by dots in the samples TU and PI. (B) Immunoblot 
of total cellular extracts of bone marrow aspirates from the 
same six patients described in A, using affinity-purified anti- 
bodies to Pbxl. Designations are the same, and Nalm-6 and 697 
cells were used as controls. 
sequently, p77 E2A-vbxl is also a bona fide E2A-Pbxl pro- 
tein in 697 cells. Finally, bands 1, 3, and 5 yielded a 
proteolytic pattern containing the diagnostic C peptide 
of p85 E2A-vbx*, and overall, that was very similar to the 
pattern of p85 E2a-vbx]. A slightly larger A peptide was 
generated by bands 3 and 5, suggesting that these pro- 
teins are more closely related to each other than to 
the other E2A-Pbxl proteins. We will refer to the pro- 
teins that comprise bands 1, 3, and 5 and p87 E2A-vbxl, 
p83 E2A-pbxl, and p72 E2A-Pbxl, respectively. 
Each of the five E2A-Pbxl proteins are present in 
bone marrow lymphoblasts from patients with 
t(1; 19)-containing pre-B ALL 
It was of interest o determine whether the five E2A- 
Pbxl proteins are contained in primary tumor cells in 
approximately the same abundance as in 697 ceils and 
thereby exclude the possibility that any one of the forms 
may have arisen uniquely in 697 cells during their estab- 
l ishment in tissue culture. Bone marrow aspirates com- 
prised of >85% leukemic cells were obtained from six 
children with t{1;19} pre-B ALL. The identity of Pbxl- 
containing proteins in these cells was determined by two 
methods. First, ceils were labeled biosynthetically with 
[aSS]methionine, and Pbxl-containing proteins were iso- 
lated from cellular extracts by immunoprecipitation {Fig. 
3A). Proteins that bound nonspecifically during immu- 
noprecipitation were identified by the use of an anti-Rb 
serum and are illustrated in the first of each set of lanes. 
The five forms of E2A-Pbxl proteins were found in cells 
from patients TU, JO, and PI. Forms 1, 2, and 3 were 
found in cells from patients PA, CH, and RE, but forms 
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4 and 5 were obscured by the presence of background 
bands, probably monoclonal IgM heavy chain. To con- 
firm the results of immunoprecipitation a alysis and 
avoid the problem of comigrating nonspecific proteins, 
an immunoblot analysis was developed, utilizing affin- 
ity-purified anti-Pbxl immunoglobulins and total cellu- 
lar proteins from lymphoblasts derived from each of the 
same patients {Fig. 3B). Immunoblot analysis represented 
a rapid and accurate diagnostic technique for the identi- 
fication of E2A-Pbxl proteins. In this analysis, no pro- 
teins were stained in extracts from the control cell line, 
Nalm-6, in the region containing E2A-Pbxl proteins in 
697 cells (lanes designated Nalm-6 and 697). Each of the 
cells from patients contained all of the same five species 
of E2A-Pbxl proteins as were found in 697 cells, and 
most are visible in Figure 3B. In particular, forms 4 and 5 
were apparent in PA, CH, and RE. The staining of E2A- 
Pbxl band 4 was approximately twofold more intense in 
lysates from 697 cells than in those from patient cells. 
The fact that all five E2A-Pbxl proteins are observed in 
all cells containing the t(1; 19) translocation strengthens 
the suggestion that the breakpoints in E2A and pbxl 
occur consistently in the same introns, join the same 
coding exons in the fully processed mRNA, and, there- 
fore, produce the same E2A-Pbxl proteins. We know 
that the 3' E2A sequences in the E2A-pbxl transcript are 
3' sequences of exon 'T '  of the E2A gene, and, conse- 
quently, the E2A breakpoints lie within the adjacent 3' 
intron, which is 4 kb in length (Kamps et al. 1990; S.-H. 
Sun, in prep.). Because 697 cells contain a fairly accurate 
representation f both the sizes and abundances ofE2A- 
Pbxl proteins that are observed in lymphoblasts of pa- 
tients exhibiting t(1; 19)-positive pre-B ALL, they repre- 
sent an appropriate choice of cells in which to study 
these proteins. 
The relative abundances of E2A-Pbxl proteins, most 
accurately reflected by immunoblot analysis (Fig. 3B, 
lane 697; Fig. 4B, lane 697}, were the same as observed 
by immunoprecipitation, i  which case 697 cells were 
labeled biosynthetically for 3 hr {Fig. 1, lane 6, 697 
cells; Fig. 2C). Each analysis suggested that form 2 
(p85 Ez^-pb'l) comprises approximately half of all Pbxl- 
containing proteins, that form 5 is least abundant, and 
that forms 1, 3, and 4 are approximately equal and inter- 
mediate in abundance. Pulse-chase analysis revealed 
that the same relative abundance of the major forms of 
E2A-Pbxl--polypeptides 2-4--is found after only a 30- 
rain label of 697 cells and that each of these proteins has 
a half-life of -4  hr. Thus, all E2A-Pbxl proteins are 
likely to be primary translation products of different 
transcripts. 
Expression of p77 a2A-vb':~, but not  p85 E2A-Pbxl, 
induces focus formation in NIH-3T3 cells 
The cDNAs encoding p85 E2A-Pbxl and p77 Ez^-Pbxl were 
each inserted into a retroviral expression vector desig- 
nated pGD (see Materials and methods), which expresses 
the neomycin resistance gene (neo) from an internal 
SV40 promoter, and the inserted cDNA from the 5' viral 
% 
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Figure 4. Expression of p85 E2A-Pbxl and p77 E2A-vbxl by retrovi- 
rus. (A) Anti-Pbxl immunoprecipitates from NIH-3T3 cells, in- 
fected by viruses encoding p85 E2 -^vbXl and p77 ~2a-vbxl. {Lane 11 
Uninfected NIH-3T3-cl2; {lane 2} NIH-3T3-cl2 infected with 
virus encoding p77EZ^-Pbxt; {lanes 3 and 4) NIH-3T3-cl2 and 
NIH-3T3-cl3, infected with virus encoding p85 E2A-Pbxl. All cells 
were infected atan m.o.i, of 1 and selected for growth in the 
presence of G418. (B) Immunoblot analysis performed using 
equivalent amounts of cellular extract, resolved by SDS-PAGE. 
Analysis of a cloned focus containing p77 E2a-vbxl {represented 
in lane 3t was included to demonstrate comigration. {Lane 11 A 
clone of NIH-3T3-cI2 expressing p77E2A-Pbxl; (lane 2) NIH-3T3 
ceils infected by the neo virus; (lanes 3 and 4) NIH-3T3-cl2 
infected at an m.o.i, of 1 with virus encoding p85 E2A-pbxl and 
p77 E2A-pbx~, respectively, and selected for growth in G418. (A 
and B} Arrows indicate the migration of a potential normal form 
of the Pbxl polypeptide. 
LTR. Constructs were transfected into NIH-3T3 cells, 
and cells expressing neo were selected in the presence of 
G418 (Geneticin). Defective viruses encoding each E2A- 
Pbxl protein were rescued by superinfection with Molo- 
ney murine leukemia virus (MLV), and their titers were 
assayed by transmission of G418 resistance. Populations 
of cells, selected for expression of each virus, were 
shown to contain proteins that comigrated with 
p85 E2A-Pbxl and p77 E2A-pbxl, translated in vitro (Fig. 
4A). The morphological effects of p8S E2A-Pbxl and 
p77 E2^-eb'l expression in fibroblasts were analyzed by 
infection of NIH-3T3-cll0 cells with each virus at a mul- 
tiplicity of one. After 12 days of growth in normal me- 
dium (no selection), many foci of varying sizes formed on 
monolayers infected with the virus encoding p77 E2^-ebx~ 
(Fig. 5, photo 3; Fig. 6, photos 3 and 6}, but only tiny areas 
of slightly increased cell density formed on monolayers 
infected by the virus encoding p85 E2A-Pbxl {Fig. 5, photo 
2; Fig. 6, photos 2 and 5). A different subclone of NIH- 
3T3, NIH-3T3-cl2, developed larger foci after infection 
by virus encoding p77 E2A-ebxl (Fig. 5, photo 4). There- 
fore, the focus-forming potential of p77 E2^-pbxl is influ- 
enced somewhat by clonotypic variations in NIH-3T3. 
On NIH-3T3 cll0, low multiplicity of infection (1000 
neo-forming units/5 × l0 s infected cells) with virus en- 
coding p77 E2A-ebxi produced mostly small foci-contain- 
ing cells that were not as refractile as those resulting 
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Figure 5. Focus-forming activity of viruses encoding p85 
E2 -^Pb,,~ and p77 E2 -^Pbx~. (Photos 1-3) 100-mm plates of NIH- 
3T3-c110, infected at an m.o.i, of 1 with neo virus (1), virus 
encoding p85 E2A-Pb~ {2), and virus encoding p77 r2A-Pb~ (3), all 
of which were stained with crystal violet after 12 days. (Photo 4}
A 35-mm dish of NIH-3T3-cl2, infected at an m.o.i, of 0.02 with 
virus encoding p77 r2^-pb~ ~, and stained with crystal violet after 
12 days. 
from higher multiplicity of infection. However, when 
cells were infected at low multiplicity with virus ex- 
pressing p77 E2A-pBx~ and selected for growth in G418, 
40% of NIH-3T3-cll colonies exhibited the transformed, 
refractile phenotype (data not shown). Therefore, normal 
cells induced suppression of the transformed phenotype. 
Three subclones of NIH-3T3 were evaluated for focus 
formation by virus encoding p85 ExA-Pbxl. All produced 
the same subtle morphological changes depicted in pho- 
tos 2 and 5 of Figure 6. 
Mutat ions in p85 E2A-Pbxl conver t  its behavior to that 
of p 77 E2A-Pbxl 
While cells infected with virus encoding p85 E2A-pbxl 
were being passaged, large foci reminiscent of those pro- 
duced by cells containing p77 E2A-pbxl arose after 8-10 
weeks. Virus from these isolated foci now induced overt 
focus formation on unselected NIH-3T3-cll, mimicking 
the effect of virus encoding bona fide p77 E2A-Pbxl. The 
identity of E2A-Pbxl protein encoded by these focus- 
forming variants was analyzed from eight clones {Fig. 
7A). All eight virus-encoded E2A-Pbxl proteins had mo- 
lecular masses quite similar to that of p85 E2A-pbxl, and 
none was identical to p77 ExA-Pbxl. Therefore, subtle mu- 
tations in p85 E2A-Pbxl, some of which slightly alter the 
mobility of p85 E2A-Pbxl, can change its biochemical ac- 
tivity to mimic that of p77 E2A-Pbxl. Because focus-form- 
ing variants of p85 E2A-Pbxl were produced by cells pro- 
ductively infected by virus encoding p85 E2A-pbxl, an ac- 
curate analysis of the ability of p85 E2A-Pbxl to induce 
growth in agar and tumors in nude mice could not be 
performed using these cells. Therefore, nonproducer 
lines of NIH-3T3 containing p77 E2A-pbxl or p85 E2A-pbxl 
were generated. 
Both p77 E2a-vbxl and p85 ~2a-pbxl are oncoproteins 
NIH-3T3-cll cells were infected with helper-free stocks 
of virus encoding p77 r2n-PbXl or p85 r2A-pb'l {Materials 
and methods) and selected in G418 for 3 weeks. As 
shown by immunoblot analysis, these NIH-3T3 cells 
contained equivalent quantities of p77 r2n-Pb'l and 
p85 E2A-pbx~ {Fig. 7B) and did not produce virus {<1 G418 
resistance unit/10 ml of supernate vs. 2 x 106/ml for 
producer cells}. After extended passage, no foci formed in 
cultures of nonproducer cells containing p85 r2n-Pb'~, in- 
dicating that the activating mutations that arose in 
p85 E2A-Pb'~ in cultures containing helper virus occurred 
Figure 6. Focal induction and growth in 
agar associated with expression of 
p85 E2^-pbxl and p77 E2^-pbxl. (Photos 1-3} 
Focus formation by infection of NIH-3T3- 
cll cells using nonselected conditions. 
{Photo 1} neo virus; (photo 2)virus encod- 
ing p85E2^-Vbxl; (photo 3) virus encoding 
p77 E2n-vbxl. (Photos 4-61 Focus formation 
by transfection of NIH-3T3-cl3 with retro- 
viral vectors using nonselected conditions. 
(Photo 4} pGD vector; (photo 5)pGD en- 
coding p85E~n-vbxl; (photo 6) pGD encod- 
ing p77 E2^-vbxl. (Photos 7-8) Colony for- 
mation by infection of NIH-3T3-cll cells 
followed by selection in G418. (Pho- 
to 7) neo virus; (photo 8) virus encoding 
p85F'2A-Pbxl; (photo 9) growth in agar by 
NIH-3T3, infected by virus encoding 
p77 r2A-pbxl. Small colonies (3-20) of cells 
are designated by the small arrows, and 
one large colony (>100 cells) by the large 
arrow. 
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Figure 7. Generation of nonproducer cell lines avoids the for- 
mation of focus-forming variants of p85 E2A-vbx~. (A, lanes 1-8) 
Immunoprecipitations f E2A-Pbxl proteins from cells infected 
by focus-forming variants of p85 E2A-vbx~. Marker proteins are 
contained in the lanes labeled p77 and p85. {B) Western blot 
analysis of E2A-Pbxl proteins in total cellular extracts of non- 
producer NIH-3T3 cells. (p85) NIH-3T3 cells infected with 
helper-free virus encoding p85E2A-Vbx~; (p77) NIH-3T3 ceils in- 
fected with helper-free virus encoding p77 E2^-vb". Samples 
from NALM-6 and 697 cells were included for verification ofthe 
molecular mass of E2A-Pbxl proteins. 
during viral replication. Nonproducer NIH-3T3 ceils 
containing p77 E2A-vbx~ and p85 E2A-vbx~ were therefore 
used to test additional oncogenic properties of these two 
E2A-Pbxl fusion proteins. Expression of p85 E2A-Pbxl and 
p77 E2A-vbx~ in nonproducer cells induced a 5- and 12-fold 
increase in the density at which cells stopped dividing 
(Table 1). Although expression of either p85 E2A-pbxl or 
p77 E2A-vbxl permitted the growth of NIH-3T3 cells in 
agar, p77 E~A-vbxt was at least 10-fold more effective than 
was p85 E2A-pbxl (Table 1; Fig. 6, photo 9}. Immunofluo- 
rescence analysis revealed that the largest colonies of 
cells that grew in agar also contained the most E2A- 
Pbxl protein (data not shown). Tumorigenicity was 
tested in nude mice by subcutaneous injection of 8 x l0 s 
cells. Nonproducer cells expressing p77 EzA-vBxl or 
p85 E2A-Pbxl formed tumors at the site of injection within 
6 weeks. Antibodies to Pbxl heavily stained a 77-kD 
protein on an immunoblot containing protein extract 
from a tumor that arose after injection of cells expressing 
p77 F2A-vbxl, indicating that the tumor grew from the 
introduced cells and was not a host proliferation in 
resonse to the introduced cells. Normal NIH-3T3 cells 
were not tumorigenic (Table 1 ). Therefore, in spite of the 
different transforming potentials of p77 E2^-vbxl and 
p85 E2A-vbx~ in cell culture assays, both proteins contrib- 
ute directly to the oncogenic conversion of NIH-3T3 
cells. 
E2A-Pbxl proteins are nuclear 
The intracellular location of p85 E2A-r'bxl and p77 E2A-Pbxl 
was determined by immunofluorescence. C lls express- 
ing both p85 E2A-pbxl and p77 ~a^-vbx~ exhibited nuclear 
fluorescence that spared the nucleoli (Fig. 8 and data not 
shown). We estimate the average abundance of each pro- 
tein in the nucleus of selected populations of NIH-3T3 to 
be approximately fivefold greater than that in the nuclei 
of 697 cells, based on Western blot analysis of equivalent 
amounts of cell extract (Fig. 4, lanes 697, 3, and 4) and 
taking into consideration the difference in protein con- 
tent per cell between fibroblasts and lymphocytes. We 
were unable to demonstrate strict nuclear localization of 
E2A-Pbxl proteins in 697 cells, because the lower levels 
of E2A-Pbxl expression required higher sensitivity, and 
cytosolic and membrane staining, a small amount of 
which is evident in the normal fibroblasts in Figure 8, 
became prominent features under these conditions. 
Normal pbxl transcripts are observed in most tissues 
in the developing and adult mouse 
Transcriptional regulation of pbxl was examined by 
analysis of the pbxl transcript during mouse develop- 
ment, in 12-, 14-, 16-, and 18-day embryos, as well as in 
specific adult tissues. The size of pbxl transcripts are 
heterogeneous, having two major species of 2.2 and 6.8 
kb {Fig. 9). The difference in size between the 2.2- and 
6.8-kb transcripts of pbxl was essentially the same as for 
the 3.2- and 8.0-kb fusion transcripts of E2A-pbxl, sug- 
gesting that alternate splicing in pbxl accounts for this 
difference of -4.8 kb. Low levels of pbxl expression 
were detected throughout embryogenesis, as well as in 
most adult tissues, and pbxl transcripts in lung and 
brain were approximately twofold more abundant, the 
6.8-kb form predominating in both tissues. Expression of 
pbxl was extremely low in spleen, consistent with our 
previous observation that pbxl is not expressed in early 
Table 1. Summary of the transforming properties of E2A-Pbxl proteins 
Growth in agar {colony size) 
Saturation density Tumor formation 
Cell type 3-20 21-100 > 100 (per 5-cm plate) in nude mice {ram 3) 
NIH-3T3 0 0 0 1.2 × 106 0 
+p85 E2A-Pbxl 782 17 7 6.0 x 106 600 
+ p77 EzA-vbxl 9350 1530 80 1.44 x 10 z 50 
Analysis was performed on nonproducer populations of NIH-3T3 expressing either p85 r2A-vbxl {designated + 85 E2A-Pxl) or p77 E2A-vbxl 
{designated +p77E2A-Vbx~). The number of colonies formed in agar was measured from plates seeded with 200,000 cells. The size of 
tumors formed in nude mice was measured 6 weeks after injection of cells. 
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A p77 E2A-Pbx 
B NEO 
Figure 8. Nuclear localization of Pbxl by indirect immunofluo- 
rescence using anti-Pbx! serum. {A) NIH-3T3-cI2 infected by 
E2A-Pbx 1 
virus encoding p77 and selected for growth in G418. 
(B} Uninfected NIH-3T3-cl2. 
transcripts cloned earlier (Kamps et al. 1990~ Nourse 
et al. 1990}. Partial proteolytic cleavage patterns of 
the other three polypeptides were related to that of 
p85 E2A-vbxl, indicating that each of these proteins re- 
presents either a post-translation modification of 
p85 E2A-Pbxl or a highly related protein translated from an 
alternatively spliced E2A-pbxl mRNA. Because none of 
the other three forms of E2A-Pbxl proteins was ob- 
served in NIH-3T3 cells expressing either p85 E2^-vbxl or 
p77 r'2A-vbx~, we favor the hypothesis that each addi- 
tional form results from alternative splicing. The sugges- 
tion that alternate splicing produces transcripts encod- 
ing these proteins is not unlikely because two different 
sequences have been found to initiate normal E2A pro- 
teins (S.-H. Sun, unpubl.}. In addition, the existence of a 
second major 8.0-kb transcript in all t(lil9}-containing 
lymphoblasts examined to date (Mellentin et al. 19891 
Kamps et al. 1990~ Nourse et al. 1990) suggests that at 
least one additional variation within the Pbx 1 portion of 
E2A-Pbxl proteins is also possible. 
The fact that p77 E:zA-r'bxl was more transforming than 
p85 r2A-vbx~ in tissue culture assays and the observation 
that subtle mutations in p85 r2A-vbx~ dramatically ele- 
vate its transforming activity suggest that a biochemical 
activity of p85 r2A-vbx~ may be regulated by a normal 
cellular mechanism and that such regulation may re- 
quire the unique 97-amino-acid carboxyl terminus of 
p85 E2A-vbx~. If so, alternate splicing would represent a
cellular mechanism that generates an activated E2A- 
Pbxl protein, p77, and might be a method used by nor- 
mal cells to regulate the activity of endogenous Pbxl. 
or mature B or T cells (Kamps et al. 19901 Nourse et al. 
19901. pbxl was also not expressed in adult testes. There- 
fore, although Pbxl contains ahomeo box, its expression 
pattern suggests that it is neither a tissue- nor a devel- 
opmental stage-specific transcription factor. Instead, the 
widespread, low-abundance expression of pbxl indicates 
that the Pbxl protein performs a more ubiquitous func- 
tion. 
Discussion 
In this study we identify five forms of E2A-Pbxl pro- 
teins in lymphoblasts having the t(1119} translocation, 
and characterize the activities of the proteins encoded by 
two cloned E2A-pbxl cDNAs. Immunoprecipitation 
and Western blot analysis were used to demonstrate hat 
each of the five forms of E2A-Pbx 1 proteins is contained 
in both the pre-B ALL cell line, 697, and in lymphoblasts 
from the marrow of children having t( l il9)-positive pre- 
B ALL. Immunoblotting with affinity-purified antibodies 
to Pbxl provided a rapid and sensitive screen for the 
presence of E2A-Pbxl proteins in t(1119)-positive lym- 
phoblasts. Comigration in SDS-PAGE and identical pat- 
terns of partial proteolysis with S. a~eus V8 protease 
suggested that two of the five E2A-Pbxl proteins were 
identical to the polypeptides encoded by each of two 
FETAL ADULT 
8 kb 
3.3 kb 
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Figure 9. Expression of pbxI in mouse development. (Top) A 
Northern blot, using a pbxl cDNA probe, and samples of 
poly{A)-selected RNAs from the indicated stages and tissues in 
fetal and adult mice. RNAs from 697 cells and NIH-3T3 cells 
are included as controls for the size of E2A-pbxl fusion tran- 
scripts and normal pbxl transcripts. {Bottom} Hybridization of 
the same blot with a probe to actin. 
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Although the absolute activities of p85 E~A-Pbxl were  
lower than those of p77 F'2A-vbx], p85 E2A-Pbxl was at least 
as good as p77 ExA-l'bxl in contributing to the tumori- 
genic conversion of NIH-3T3, as assayed by tumor for- 
mation in nude mice. Therefore, both forms of E2A- 
Pbxl proteins may well alter the growth or development 
of pre-B lymphocytes, coincident with acquisition of the 
t{ 1; 191 translocation. 
The transformation potential of E2A-Pbxl proteins 
may also differ when they are expressed in fibroblasts 
and pre-B lymphocytes. Because normal pbxl is tran- 
scribed in NIH-3T3 fibroblasts but not in pre-B cells, 
E2A-Pbxl protein would presumably compete for bind- 
ing DNA with endogenous Pbxl proteins in fibroblasts 
but would bind unchallenged in pre-B cells. As a result of 
such competition, more E2A-Pbxl protein might be 
needed to induce penetrance of the tumorigenic pheno- 
type in fibroblasts than in pre-B cells. The positive cor- 
relation between the abundance of E2A-Pbxl protein 
and the ability of cells to grow as colonies in agar may 
reflect one example of behavior consistent with such a 
hypothesis. Our observation that l rger loci are formed 
when NIH-3T3 cells are exposed to higher titers of virus 
encoding p77 E2A-Pbxl also supports this contention. Ex- 
amination of the effects of E2A-Pbx 1 expression in pre-B 
lymphoid cells will be required to further clarify this 
question. 
In an effort tO clarify the effects of p85 E2A-pbxl and 
p77 E2A-Pbxl in lymphocytes, we expressed each in the 
IL3-dependent cell lines BA/F3 and LyD-9. Neither pro- 
tein affected either the absolute or relative dependence 
of these cell lines on IL3 for growth. Consequently, we 
conclude that these two E2A-Pbxl proteins do not be- 
have as does BCR-ABL, or activated cytosolic or trans- 
membrane tyrosine protein kinases, whose expression 
obviates the growth factor dependence of these and sim- 
ilar IL3-dependent cells (Daley and Baltimore 1988; 
Kipreos and Wang 1988; Pierce et al. 19881 Sherr 1988}. 
Experiments are now under way to determine whether 
p85 E2A-pbxl or p77 E2A-PbX] themselves, or in combina- 
tion with growth factors or other oncoproteins, can in- 
duce lymphoid transformation. 
The normal pbxl gene is clearly transcribed in many 
cell types. Major transcripts of 2.2 and 6.8 kb, as well as 
a variety of intermediate, less abundant forms, were ex- 
pressed at approximately equal levels in many tissues. 
Because pbxl is also expressed in 12-, 14-, 16-, and 18- 
day embryos with little variation in abundance, we con- 
clude that Pbxl performs a widespread function that is 
either not required or detrimental to the development of
B and T cells. We are now cloning the normal pbxl tran- 
script to determine the size and properties of the amino- 
terminal domain of Pbxl that is not present in the E2A- 
Pbxl fusion protein. Immunoprecipitation a alysis ug- 
gests that a normal Pbx protein may be -42  kD, because 
an antigen of this size reacts with anti-Pbxl sera in NIH- 
3"I'3 fibroblasts, but not in pre-B cells {Fig. 4). This would 
predict that 55 amino-terminal residues of Pbxl are not 
contained in E2A-Pbxl. However, in our efforts to clone 
a full-length pbxl transcript, we have cloned a highly 
related cDNA, denoted pbx2, that is transcribed from a 
clearly distinct genetic locus and would most l ikely also 
react with anti-Pbx antisera. Therefore, we do not know 
whether the 42-kD protein is Pbxl, Pbx2, or another 
member of a potentially larger family of Pbx proteins. 
Cloning of the 5' end of pbxl will permit us to address 
two key questions in understanding the biological activ- 
ity of E2A-Pbxl proteins: Does the E2A amino-terminal 
domain contribute an active or passive role in the bio- 
chemistry of E2A-Pbxl fusion proteins, and must the 
normal amino-terminal sequences of Pbxl be removed to 
create a transforming protein? It is possible that the role 
of E2A in t(l~ 19)pre-B ALL may be simply to induce the 
production of Pbxl in these cells. Alternatively, the 
amino-terminal transcriptional activation domain of 
E2A may be indispensable for transformation-associated 
properties of E2A-Pbxl proteins. It is also possible that 
the amino-terminal sequences of Pbxl may repress its 
activity and would need to be deleted to form an onco- 
protein. Although these questions can, in part, be ad- 
dressed by expression of proteins in NIH-3T3 cells, an 
animal model involving E2A-Pbxl-mediated leukemo- 
genesis in mice will inevitably be required to evaluate 
fully the functional domains essential in the induction 
of pre-B ALL by E2A-Pbxl proteins. 
Materials and methods 
Production and purification of GST-Pbxl fusion protein 
The oligonucleotide, 5'-GTGTTTTGAGAATTCGAGGAGC- 
CC-3', was used to introduce an EcoRI site 6 nucleotides to the 
3' side of the junction between E2A and pbxI sequences in the 
E2A-pbxl eDNA clone, pBSK:E2A-pbxI-II. The pbxl se- 
quences, now flanked by EcoRI sites, were ligated into the 
EcoRI site of pGEX-2T (Amrad, Australia), a bacterial vector 
that expresses cloned cDNAs as glutathione S-transferase (GST) 
fusion proteins. The resulting GST-Pbxl protein contains 28
kD of Pbxl and has a predicted molecular mass of 56 kD. 
p56 GsT-Pbxl was isolated from the insoluble fraction of bacterial 
extracts for immunization {see Preparation of antisera to Pbxl, 
below) and by adsorption to glutathione agarose (Sigma) and 
eluted with free glutathione (Sigma] for the purification of 
soluble p56 GsT-vbxl as specified by Amrad. A majority of 
p56 GsT-Pbxl was insoluble, but 5% could be isolated as soluble 
protein. Once purified, the DNA-binding properties of these 
GST-Pbxl proteins was tested by adsorption to calf thymus 
DNA-agarose (Sigma), followed by elution with increasing con- 
centrations of salt. A total of 1.3 mg of GST-Pbxl protein was 
incubated with 0.4 ml of DNA-agarose (containing 1.0 mg/ml 
of bound DNA) in a total of 3 ml of 50 mM Tris {hydroxymethyl) 
aminomethane (Tris; pH 7.1}, 100 mM NaCI {TN} with contin- 
uous agitation for 2 hr at 4°C. After 2 hr, the resin was allowed 
to settle in the column, a flowthrough fraction was collected, 
and the column was washed three times with 1.5 column vol- 
umes (CV) of TN. Proteins that bound the DNA were eluted by 
washing the resin with 1.5 CV of TN containing NaCI concen- 
trations that were increased by 100 mM increments. 
Preparation of antisera to Pbxl 
Fifty mill i l iters of bacteria containing the pGEX-2T-pbxl ex- 
pression plasmid were induced for 2 hr with 100 V.M IPTG, as 
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specified by Amrad. The bacteria were pelleted by centrifuga- 
tion, resuspended in 1S ml of 100 mM EDTA, 1% NP-40 (Sigmal, 
1% aprotinin (Sigma), and disrupted by sonication. At this 
point, 90% of the GST-Pbxl fusion protein was contained in 
the insoluble material. Insoluble GST-Pbxl was isolated by 
centrifugation at lO, O00g for 10 min at 4°C. The yield of insol- 
uble GEX-Pbxl fusion protein was -1200 lag/50 ml of initial 
bacterial culture. This pellet was solubilized in 2 ml of SDS 
containing sample buffer, and the equivalent of 600 vLg of GST- 
Pbxl protein was fractionated by SDS-PAGE, using a gel 2 mm 
thick. After completion of electrophoresis, GST-Pbxl was vi- 
sualized as a band of precipitated protein-SDS complexes after 
incubation i  2.0 M KC1 for 30 min at 4°C. The band was excised 
and equilibrated in water for 30 min. One-third of this gel slice 
was emulsified with two volumes of complete Freund's adju- 
vant and one volume of water. Rabbits were injected with a 
total of 100 vLg of GST-Pbxl at six intradermal locations on 
their backs and boosted 4 weeks later using the same protocol 
with the substitution of incomplete for complete Freund's ad- 
juvant. Four weeks after the first boost, the serum was tested for 
its ability to immunoprecipitate Pbxl-containing proteins from 
697 cells. Each of two rabbits subjected to this protocol pro- 
duced a titer of anti-Pbxl antibodies by which 1 ~1 of serum was 
capable of immunoprecipitating all of the five E2A-Pbxl pro- 
teins from 5 x 10 6 cells. 
Biosynthetic labeling, immunoprecipitation, a d partial 
proteolysis 
Both lymphocytes and fibroblasts were labeled biosynthetically 
with 200 ~Ci of [aSSImethionine (Amersham) for 3 hr in 1 rnl of 
methionine-free DMEM, containing 20% dialyzed fetal bovine 
serum and 50 ~M 2-mercaptoethanol. After 3 hr, the cells were 
washed once in PBS and lysed in 400 ~tl of 50 mM Tris (pH 7.4), 
300 mM NaC1, 0.1% NP-40, 1 mM PMSF, 5 mM EDTA, and 1 mM 
DTT (ELB buffer). Lysates were clarified by centrifugation at
10,000g for 1.5 hr. Portions of this cellular extract were sub- 
jected to immunoprecipitation according to published condi- 
tions (Sefton et al. 1978}, using ELB buffer for all washes, and 
analyzed by SDS-PAGE using 10% acrylamide gels with low 
bis-acrylamide concentrations. Gels were processed using 
DMSO containing 20% PPO to enhance the signal from radio- 
active proteins. Partial proteolysis was performed in the gel ac- 
cording to the method of Cleveland et al. (1977), and peptides 
were resolved by SDS-PAGE using 20% acrylamide gels with 
low bis-acrylamide concentrations. 
Affinity purification of antisera 
A total of 0.75 mg of GST-Pbxl proteins, purified from bacterial 
extracts by affinity to glutathione-agarose (see Production and 
purification of GST-Pbxl fusion protein, above) was coupled to 
0.4 ml of Affi-gel 10 in 100 mM 3-(N-morpholino)-propanesul- 
fonic acid (MOPS) (pH 7.0) buffer according to the manufactur- 
er's protocol (Bio-Rad). The resin was washed twice at 4°C in 10 
ml of PBS, twice in 10 ml of I00 mM glycine {pH 2.8), and twice 
in 10 ml of PBS. Rabbit anti-Pbx-1 serum (12 ml) was applied to 
the resin in a column four times. The resin was washed four 
times with 10 ml of PBS. Immunoglobulins were eluted by con- 
secutive addition of ten 600-~1 volumes of 100 mM glycine (pH 
2.8), and each eluted fraction was collected into a tube contain- 
ing 60 ~1 of 1.0 M Tris (pH 8.05), to immediately neutralize the 
pH. A total yield of 1.7 mg of immunoglobulin was obtained. 
Western blotting protocol 
Lymphocytes were solubilized by boiling in SDS-containing 
Laemmli sample buffer at a concentration f 2 x 107/ml. These 
samples (30 ~1) were resolved by SDS-PAGE and transferred to 
nitrocellulose in 10 mM 3-[cyclohexylamino]- 1-propanesulfonic 
acid {CAPS) {pH 10.8), 20% methanol, at 0.5 amp for 45 rain at 
4°C. A Western blotting protocol (Promega) was followed, using 
10 ~g/ml anti-Pbxl imrnunoglobulin to bind Pbxl-containing 
proteins and alkaline phosphatase-conjugated, goat anti-rabbit 
immunoglobulin to detect the location of rabbit antibodies 
bound to Pbxl. 
Construction of expression vectors 
The retroviral expression vector pGD, the parental vector of 
pGD210 (Daley et al. 1990), was obtained from Marty Scott, 
who had converted a non-unique XhoI site into a unique BclI 
site to facilitate the cloning of various cDNAs. The cDNAs of 
both type I and type II E2A-pbxI, encompassing sequences from 
the 5' end described previously (Kamps et al. 1990) to the unique 
DraI site located in both 3'-noncoding regions {residue 2851 in 
the type I transcript; Kamps et al. 1990), were ligated into the 
BclI site, after addition of BclI linkers to the inserts. Each plas- 
mid was transfected into NIH-3T3 cells using the calcium phos- 
phate technique (Shih et al. 1979}. 
Generation of helper-free virus 
The ecotropic packaging cell line, tD-CRE, was transfected with 
the retroviral constructs described above. Transfected cells, se- 
lected for construct expression by growth in G418 for 2 weeks, 
were cloned by growth in 96-well plates from single cells and 
screened for expression of virus by RNA dot blot analysis. 
Clones expressing the most virus were expanded, and the viral 
titer of supematants analyzed. The titer of tD24L, a clone ex- 
pressing virus encoding p85 E2A-pbxl, was 5 x 105 G418-resis- 
tance units per milliliter, whereas that of 481 S, a clone express- 
ing virus encoding p85 E2A-Pbxl, was 5 x 10 a. 
Cells, viral infections, and soft agar assays 
NIH-3T3 cells were obtained from Paul Kaplan. Both normal 
and infected NIH-3T3 cells were grown in Dulbecco-Vogt mod- 
ified Eagle medium (DMEM) containing 5% calf serum. Viral 
infections were performed for 2 hr in 2 ml of the same medium 
containing 8 ~g/ml Polybrene, then diluted to 10 ml and incu- 
bated overnight. The medium was changed the following morn- 
ing. Selection for cells expressing the neomycin resistance gene 
(neo) was performed in DMEM containing 5% calf serum and 
500 }zg/ml of G418 (Geneticin, GIBCO). Incubation with selec- 
tive medium was initiated 2 days after infection. Soft agar as- 
says were performed using 200,000 cells resuspended in DMEM 
containing 5% calf serum, and 0.2% Noble agar, and with a base 
layer of 0.6% Noble agar. Colonies were scored after 20 days. 
697 cells were grown in RPMI medium supplemented with 20% 
fetal bovine serum, 2 mM glutamine, and 50 ~M 2-mercaptoeth- 
anol. Primary pre-B ALL cells were obtained from bone mar- 
row aspirates of patients having t(1; 19)-positive leukemias, 
based on cytogenetic analysis conducted by Dr. Susana Rai- 
mondi. Leukemic ells were isolated by Ficoll-Hypaque density 
gradient centrifugation and viably cryopreserved in medium 
containing 10% dimethylsulfoxide. Each patient or patient's 
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guardian was advised of the procedures and risks, in accordance 
with institutional guidelines, and gave informed consent. 
Immunofluorescence 
NIH-3T3 cells were grown on coverslips coated with fibronec- 
tin (Sigma) as follows. Fibronectin ( 1.0 mg) was dissolved gently 
without vortexing in a volume of 1 ml of water at 37°C for 30 
rain. Twenty milliliters of this solution was diluted to 1 ml in 
DMEM. Aliquots (100 ~1) of the diluted fibronectin were added 
directly to untreated coverslips, and incubated at 37°C for 30 
rain in a tissue-culture incubator. Coverslips were rinsed with 
PBS twice and used immediately for growth of cells. Cells, 
grown on the fibronectin-treated coverslips, were prepared for 
immunofluorescence by fixation in 3% paraformaldehyde (pH 
7.4) in PBS and permeabilized with 1.0% NP-40. E2A-Pbxl pro- 
teins were identified by incubation using a 1 : 300 dilution of 
anti-Pbxl serum followed by incubation with affinity-purified, 
rhodamine-conjugated donkey anti-rabbit antibodies (Jackson 
ImmunoResearch Laboratories) and visualized by fluorescence 
microscope as described (Van Etten et al. 1989). 
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